Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Celcuity Presented Phase 1 Data At ESMO 2025 Showing Gedatolisib Plus Darolutamide Delivers 9.1-Month Median rPFS In mCRPC With Favorable Safety Profile And No TRAE-Related Discontinuations

Author: Benzinga Newsdesk | October 20, 2025 03:18am

Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67%
No patients discontinued study treatment due to a treatment-related adverse event ("TRAE")

Posted In: CELC